IND supports Phase 1/2/3 study that will evaluate safety and efficacy at 24 weeks The first patient in the ongoing Multi-Patient Expanded Access study has surpassed seven months kidney function; a ...
Phase 2 trial, expected to begin in 1H 2024, aims to address the unmet medical need of patients suffering from stage 2 or 3 acute kidney injury with associated acute hypoxemic respiratory failure, a ...
The MarketWatch News Department was not involved in the creation of this content. -- Break Wave represents the future of kidney stone treatment with the potential to become a first-line treatment ...
Paragonix Technologies Receives FDA 510(k) Clearance for KidneyVault Portable Renal Perfusion System
WALTHAM, Mass.--(BUSINESS WIRE)--Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, received U.S. Food and Drug Administration (FDA) 510(k) clearance ...
Please provide your email address to receive an email when new articles are posted on . Facing barriers to innovation in kidney care, startups can engage with business incubators for support. The team ...
Break Wave represents the future of kidney stone treatment with the potential to become a first-line treatment option The Break Wave device non-invasively fragments stones in the kidney or ureter on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results